Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
A Phase II Study of Low Dose Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer
Sponsor: NewLink Genetics Corporation
Terminated
Sponsor proceeded with a phase III study for same indication.
Other terminated trials from NewLink Genetics Corporation
- Non-small Cell Lung Cancer · Phase PHASE1 · Jan 2021
- Metastatic Melanoma · Phase PHASE2 · Jan 2021
- Pancreatic Cancer · Dec 2020
- Melanoma · Phase PHASE2 · Nov 2019
- Ovarian Cancer · Phase PHASE1/PHASE2 · Oct 2018
More terminations from NewLink Genetics Corporation
This PHASE2 trial investigates Pancreatic Cancer and is currently terminated or withdrawn. NewLink Genetics Corporation leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jun 2020 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NewLink Genetics Corporation
For direct contact, visit the study record on ClinicalTrials.gov .